HCPCS G9839: Anti-EGFR Monoclonal Antibody Therapy - OpenPayer

Summary & Overview

HCPCS G9839: Anti-EGFR Monoclonal Antibody Therapy

HCPCS Level II code G9839 denotes anti-EGFR monoclonal antibody therapy, a biologic infusion used in oncology to inhibit the epidermal growth factor receptor. This therapy is clinically significant for cancers where EGFR drives tumor growth and can involve complex administration and monitoring needs. Nationally, accurate coding for biologic oncology agents affects payment, utilization tracking, and quality measurement for infusion services.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical purpose and typical sites of service, plus benchmarking context and payer coverage considerations where available. The publication summarizes common modifiers used with this service and highlights policy or reimbursement elements relevant to infusion centers and hospital outpatient departments.

The article provides: clear identification of the code and clinical context, a summary of payer coverage scope, common billing practices associated with monoclonal antibody infusions, and where to look for policy updates or coding guidance. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9839HCPCS Level IImonoclonal antibodyanti-EGFRoncology infusionbiologic therapyinfusion centerhospital outpatient

Billing Code Overview

HCPCS Level II code G9839 represents anti-EGFR monoclonal antibody therapy. This code denotes administration of a biologic therapy that targets the epidermal growth factor receptor (EGFR), typically used in oncology care where EGFR inhibition is indicated.

Service Type: Biologic infusion/monoclonal antibody therapy

Typical Site of Service: Outpatient infusion center or hospital outpatient department

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with an advanced or metastatic epithelial malignancy demonstrating epidermal growth factor receptor (EGFR) pathway activation or EGFR-expressing tumor cells. The patient presents to an outpatient oncology infusion center for administration of an anti‑EGFR monoclonal antibody (G9839) as part of systemic therapy. The clinical workflow includes pre‑infusion evaluation (vital signs, performance status review, and review of laboratory values such as complete blood count, liver function tests, and electrolytes), confirmation of indication and consent, infusion preparation by pharmacy, administration via peripheral or central intravenous access, and post‑infusion monitoring for infusion reaction or dermatologic toxicity. Common concurrent activities include documentation of tumor molecular testing supporting EGFR targeting, scheduling of follow‑up oncology visits, and coordination of supportive medications (antihistamines, corticosteroids, antipyretics). Typical sites of service are outpatient hospital infusion centers, freestanding oncology infusion clinics, or physician office infusion suites. Patient scenario example: a 62‑year‑old with metastatic colorectal adenocarcinoma with documented wild‑type RAS and overexpressed EGFR receiving the first cycle of an anti‑EGFR monoclonal antibody infusion with premedication and observation for two hours post‑infusion for potential hypersensitivity reaction.

Coding Specifications

Modifier	Description	When to Use
`22`

HCPCS G9140: Frontier Extended Stay Clinic Demonstration

HCPCS-G8874-EXCISED-TISSUE-WITHOUT-INTRAOPERATIVE-IMAGING-CONFIRMATION

HCPCS G8874: Excised Tissue Without Intraoperative Imaging Confirmation

HCPCS-G2170-PERCUTANEOUS-ARTERIOVENOUS-FISTULA-CREATION-THERMAL

HCPCS G2170: Percutaneous Arteriovenous Fistula Creation Using Thermal Resistance Energy

HCPCS-G8762-PARKINSONS-DISEASE-QUALITY-COMPLETE

HCPCS G8762: Parkinson's Disease Quality Measures Completed

HCPCS-G9050-ONCOLOGY-EVALUATION-STAGING-INITIAL-WORKUP

HCPCS G9050: Oncology Evaluation and Staging at Diagnosis or Recurrence

HCPCS-LEVEL-II-G9734-PATIENT-REFUSED-PARTICIPATION

HCPCS Level II G9734: Patient Refused to Participate

HCPCS-G0909-HEMOGLOBIN-NOT-DOCUMENTED

HCPCS G0909: Hemoglobin Level Not Documented, Reason Not Given

HCPCS-G6011-COMPLEX-MULTI-FIELD-RADIATION-THERAPY-DELIVERY

HCPCS G6011: Complex Multi-Field Radiation Therapy Delivery

HCPCS-G9626-MEDICAL-REASON-NOT-REPORTING-BLADDER-INJURY

HCPCS G9626: Medical Reason for Not Reporting Bladder Injury

HCPCS-G9111-HEAD-AND-NECK-SQUAMOUS-CELL-DISEASE-STATUS

HCPCS G9111: Head and Neck Squamous Cell Cancer Disease Status

Showing 1–10 of 1996

Taxonomy Code	Specialty	Notes
`208000000X`	Medical Oncology	Most common specialty ordering and managing anti‑EGFR monoclonal antibody therapy.
`207RG0100X`	Hematology‑Oncology	Specialists who manage systemic anti‑cancer biologic infusions.
`363L00000X`	Infusion Therapy	Nurses and infusion specialists who administer monoclonal antibody infusions.
`207S00000X`	Surgical Oncology	May be involved in comprehensive cancer care when systemic therapy is coordinated with surgical management.
`3336C0002X`	Oncology Nurse Practitioner	Advanced practice clinicians who manage evaluation, premedication orders, and follow‑up care.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.7`	Malignant neoplasm of sigmoid colon	EGFR monoclonal antibodies are used in some metastatic colorectal cancers depending on RAS status.
`C18.9`	Malignant neoplasm of colon, unspecified	General colon cancer diagnosis that may warrant anti‑EGFR therapy in appropriate molecular contexts.
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Anti‑EGFR therapies can be used in select non‑small cell lung cancers with EGFR pathway relevance.
`C50.912`	Malignant neoplasm of unspecified site of left female breast	Some EGFR‑targeted therapies are considered in breast cancer subtypes or clinical trials.
`C71.9`	Malignant neoplasm of brain, unspecified	Investigational use of anti‑EGFR agents may occur for certain brain tumors; included for completeness in advanced disease contexts.
`Z85.038`	Personal history of malignant neoplasm of large intestine	Relevant for follow‑up or recurrence management when anti‑EGFR therapy is considered for metastatic recurrence.
`D49.1`	Neoplasm of uncertain behavior of skin	EGFR inhibitors have dermatologic relevance; listed for conditions where biologic therapy may be considered.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial drug	Commonly used for billing IV infusion time for monoclonal antibody administration when the infusion duration fits the time bracket.
`96415`	Chemotherapy administration, IV infusion; each additional hour (List separately in addition to code for primary service)	Used to report additional infusion time beyond the initial hour when applicable.
`96417`	Chemotherapy administration, IV infusion; each additional hour (when intensive monitoring)	Used when extended monitoring requires reporting of additional hourly infusion time under specific payer rules.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	May be used in some outpatient settings for therapeutic biologic infusions if chemotherapy series codes are not applicable per payer policy.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non‑biologic or biologic agent	Used when the anti‑EGFR monoclonal antibody is administered subcutaneously or intramuscularly (if an approved formulation/route applies).
`99406`	Smoking and tobacco use cessation counseling, intermediate, greater than 3 minutes up to 10 minutes	Example of an ancillary counseling CPT sometimes billed during oncology visits; included when counseling services are documented during the encounter.

OpenPayer